Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
about
Thalidomide and thalidomide analogues for induction of remission in Crohn's diseaseTumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseCDP-870 (certolizumab) in rheumatoid arthritisSevere and steroid-resistant Crohn's diseaseMedical management of Crohn's disease: current therapy and recent advances.Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis.Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseNew biologics in the management of Crohn's disease: focus on certolizumab pegol.Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysisVedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison.Evolving knowledge and therapy of inflammatory bowel disease.Safety of biologic therapy.Innovative therapeutics for inflammatory bowel diseaseTreatment of inflammatory bowel disease: a review of medical therapy.Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease.Investigational agents for Crohn's disease.Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.An evidence-based systematic review on medical therapies for inflammatory bowel disease.Certolizumab pegol in the treatment of Crohn's disease.Biological therapies for rheumatoid arthritis: progress to date.Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis.Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.New biologic therapeutics for ulcerative colitis and Crohn's disease.Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.Safety considerations when using anti-TNFα therapy to treat Crohn's disease.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability.Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials.Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials.Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.Treatment of Crohn's disease with certolizumab pegol.Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα).
P2860
Q24241766-AB17AB87-D4F5-4387-A44C-E254B67302AAQ24242101-04413E78-1E02-4EE8-93B2-E547D7D6D50FQ28254498-6ECC78DB-0771-4BF0-80BE-DF864F4B3D83Q28266806-132C4ED0-62DD-441A-988B-B279D604B349Q30450875-4726373D-B006-42AB-8FBF-4D08156DC0BFQ30486142-6268BE40-60B9-4EDD-AF92-3707BA5FA148Q34275637-DF26D546-837B-4B7F-86F0-4CFE3679C20DQ34353032-2BDF7D19-1EEC-4487-B272-0D08100ADD70Q34449843-363317CB-750F-411D-A27E-D240EA3997FEQ35026264-D148802D-799B-4718-8AF7-5C045604CB49Q35052356-97CB604E-6237-4C23-BC5B-DF8D4BA74D3FQ36049752-1F9AC959-94CD-4CBB-ABCE-1B13808F0C71Q36414506-D57F3D63-830F-4A9E-8738-F0791E7EE65CQ36737339-D8C671E3-57FF-4923-AE45-D7B48BC85701Q36802524-3FD483DB-71FC-456A-AF91-1470FE9AC08DQ37058862-05D6D748-B19A-4483-904D-474D08186A49Q37684572-7CE294A9-1C7F-4D34-8233-1F8DBC1F20E2Q37704520-53A726DE-6D76-4D89-9E66-CEBC5F01FE44Q37788217-3A96B9A6-99DC-4B61-ADE5-3E67B5313726Q37789693-FACEDDEF-005C-42CB-B2FB-B34ED865E4EFQ37853359-7730E8DA-6840-47F1-9840-FEA23B8C0AB6Q37862584-246EE0CE-235F-4605-BB8E-9DA6EE7B6EC5Q38085665-0572365B-482C-4200-88D8-ADE0BD5A9FEDQ38096206-210A0C79-7394-4A6F-990B-6FF114F1D81AQ38104612-EBB75E99-F050-4757-AB5A-DFDE8E27009BQ38128946-C48DB3F8-8409-4349-A2D0-2959811A2FCBQ38180195-F4C6B0B3-FC63-4ADE-9E74-ED9536AF250EQ38185687-CB08DD88-2296-4E2D-B315-B4DDB6D474F0Q38238100-D9F9D995-E35E-41AA-A824-D03FC15A6726Q38268598-68EDCB94-C942-4F18-8ACD-606E27875D2DQ38317338-21FB06F8-FE11-4780-8558-925FE07D2A25Q38425123-4EA6EDEA-2885-4D48-835F-DFB12B600E52Q39121473-720A216D-4688-4AA5-B2A6-4D4EC24035EBQ41219043-C88FE866-3FA7-4B99-9598-77E95771DBEDQ41934485-658F8B93-BA82-474A-B0FB-1B4EA9568237Q42281646-7EF5CAA2-81D5-41A2-8DBA-0BD99A7364FBQ47862084-6EEAB318-C267-4A8C-A2AC-9C0F3B333F85Q50923712-5393FC53-70BA-4B2E-AF46-88EB46028900Q55506747-354F8F14-A241-4A4B-899E-B3568FEBA759
P2860
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@ast
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@en
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@nl
type
label
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@ast
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@en
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@nl
prefLabel
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@ast
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@en
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@nl
P2093
P2860
P921
P1476
Intravenous CDP870, a PEGylate ...... disease: an exploratory study.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2036.2004.02285.X
P407
P577
2004-12-01T00:00:00Z